80.5% of women with ADHD report symptoms affected by hormonal changes; 68.2% worsen premenstrually, 55.9% during perimenopause. Women are diagnosed 3.5 years later on average, and 70% receive antidepressants before any ADHD diagnosis. The estrogen-dopamine axis explains cyclical symptom fluctuations: high estrogen (follicular phase) improves dopamine signaling, low estrogen (late luteal, postpartum, menopause) worsens ADHD. Evidence for cyclical medication adjustment is preliminary but 70% of women who self-adjusted reported benefit.
24 sources 3/4 moderate Updated 2026-04-15
For women unwilling or unable to use HRT, a targeted nutraceutical stack — anchored by magnesium bisglycinate, omega-3 fatty acids, and vitamin D3+K2 — offers moderate evidence for reducing vasomotor symptoms, improving sleep quality, and stabilizing mood during the menopausal transition. Maca (Lepidium meyenii) shows promising evidence for FSH/LH modulation and hot flash reduction, particularly in early postmenopausal women. DIM (diindolylmethane) may support favorable estrogen metabolism ratios but direct symptom evidence remains limited; it requires caution in women with estrogen-sensitive conditions. No supplement replaces HRT for severe vasomotor symptoms — be honest about that limit.
16 sources 3/4 moderate Updated 2026-04-15